Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

160.87USD
18 Sep 2020
Change (% chg)

$0.40 (+0.25%)
Prev Close
$160.47
Open
$160.11
Day's High
$161.97
Day's Low
$159.34
Volume
1,208,743
Avg. Vol
486,790
52-wk High
$165.82
52-wk Low
$90.20

Latest Key Developments (Source: Significant Developments)

Zoetis Sets Quarterly Dividend Of $0.164 Per Share
Friday, 4 Oct 2019 

Oct 3 (Reuters) - Zoetis Inc ::SETS QUARTERLY DIVIDEND OF $0.164PER SHARE.  Full Article

Zoetis Names Kristin Peck To Succeed Juan Ramón Alaix As CEO On Jan. 1, 2020
Thursday, 3 Oct 2019 

Oct 3 (Reuters) - Zoetis Inc ::ZOETIS NAMES KRISTIN PECK TO SUCCEED JUAN RAMÓN ALAIX AS CEO ON JANUARY 1, 2020.ZOETIS INC - ALAIX TO RETIRE AS CEO EFFECTIVE DECEMBER 31, 2019.ZOETIS INC - ALAIX WILL ACT AS ADVISOR ON LEADERSHIP TRANSITION THROUGH DECEMBER 31, 2020.ZOETIS INC - KRISTIN PECK WILL SUCCEED JUAN RAMÓN ALAIX AS CHIEF EXECUTIVE OFFICER OF ZOETIS, EFFECTIVE JANUARY 1.ZOETIS INC - PECK JOIN BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY.  Full Article

Zoetis Announces Acquisition Of Platinum Performance
Monday, 22 Jul 2019 

July 22 (Reuters) - Zoetis Inc ::ZOETIS ANNOUNCES THE ACQUISITION OF PLATINUM PERFORMANCE, A LEADING NUTRITION-FOCUSED ANIMAL HEALTH BUSINESS FOR EQUINE AND PETCARE MARKETS.ZOETIS INC - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..ZOETIS INC - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..ZOETIS INC - DOES NOT EXPECT TRANSACTION TO HAVE A MATERIAL FINANCIAL IMPACT TO ITS GUIDANCE FOR FULL-YEAR 2019..  Full Article

EMA Says CVMP Adopted By Consensus Positive Opinion For Grouped Type II Variation Application For Suvaxyn PRRS MLV
Tuesday, 23 Apr 2019 

April 23 (Reuters) - EMA::CVMP ADOPTED BY CONSENSUS A POSITIVE OPINION FOR A GROUPED TYPE II VARIATION APPLICATION FOR SUVAXYN PRRS MLV.ADOPTED BY CONSENSUS A POSITIVE OPINION FOR THE RENEWAL OF THE MARKETING AUTHORISATION FOR OSURNIA.CVMP ALSO REVIEWED THE PSUR FOR CYTOPOINT AND RECOMMENDED AMENDMENTS TO THE PRODUCT INFORMATION.  Full Article

Zoetis Sees FY 2019 Adjusted Earnings Per Share $3.42 To $3.52
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Zoetis Inc ::ZOETIS REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.79.Q4 EARNINGS PER SHARE $0.71.Q4 REVENUE $1.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.52 BILLION.SEES FY 2019 EARNINGS PER SHARE $2.83 TO $2.99.SEES FY 2019 REVENUE $6.175 BILLION TO $6.3 BILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.42 TO $3.52.Q4 EARNINGS PER SHARE ESTIMATE $0.77 -- REFINITIV IBES DATA.FOR FULL YEAR 2019, EXPECT OPERATIONAL GROWTH OF 7.5% TO 9.5% IN REVENUE AND 8% TO 11% IN ADJUSTED NET INCOME.FY2019 EARNINGS PER SHARE VIEW $3.44, REVENUE VIEW $6.23 BILLION -- REFINITIV IBES DATA.  Full Article

Zoetis Announces Authorization Of $2 Billion Share Repurchase Program
Thursday, 13 Dec 2018 

Dec 12 (Reuters) - Zoetis Inc ::ZOETIS ANNOUNCES AUTHORIZATION OF $2 BILLION SHARE REPURCHASE PROGRAM.ZOETIS INC - DECLARED A Q1 2019 DIVIDEND OF $0.164 PER SHARE.ZOETIS INC - CO'S PREVIOUS $1.5 BILLION SHARE REPURCHASE PROGRAM, IS EXPECTED TO BE COMPLETED IN H1 OF NEXT YEAR.ZOETIS INC - BOARD DECLARED Q1 2019 DIVIDEND OF $0.164 PER SHARE, INCREASE OF 30% FROM QTRLY DIVIDEND RATE PAID IN 2018.  Full Article

BRIEF-Trianni And Zoetis Announce Agreement To Develop A Transgenic Antibody Discovery Platform For Use In Animal Health

* TRIANNI AND ZOETIS ANNOUNCE AGREEMENT TO DEVELOP A TRANSGENIC ANTIBODY DISCOVERY PLATFORM FOR USE IN ANIMAL HEALTH